<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714246</url>
  </required_header>
  <id_info>
    <org_study_id>PSU 26983</org_study_id>
    <nct_id>NCT00714246</nct_id>
  </id_info>
  <brief_title>Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II study. The phase I portion of the study will determine the maximum
      tolerated dose of bortezomib when administered in combination with carboplatin &amp; docetaxel
      and to determine the efficacy of the combination for patients with advanced NSCLC. Phase II
      will utilize the dosage determined in the Phase I and implement regimen to determine time to
      progression, overall survival, and changes in serum proteomics patterns before &amp; after
      combination therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A chemotherapy efficacy plateau' has been reached for the treatment of patients with advanced
      or metastatic non-small cell lung cancer. Platinum-based two-drug combination is considered
      the current standard of care for the treatment of advanced NSCLC. There is a need to develop
      novel regimens to improve the outcome for patients with advanced NSCLC. The combination of
      carboplatin and docetaxel is effective for therapy of advanced NSCLC. This combination
      results in improved survival and quality of life for patients with advanced NSCLC. Docetaxel
      exhibits preclinical synergy with bortezomib.

      The trial was intended to be a phase I/II study to define the maximum tolerated dose of
      bortezomib that can be administered in combination with docetaxel and carboplatin and
      subsequently evaluate the efficacy of the regimen for patients with advanced NSCLC. However,
      the trial never moved past the phase I portion of the study and was terminated early.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine maximum tolerated dose of bortezomib when administered in combination with carboplatin &amp; docetaxel for treatment of patients with advanced NSCLC cancer. Determine the response rate of the combination for patients with advanced NSCLC.</measure>
    <time_frame>Expected average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define dose-limiting toxicities of the combination of carboplatin, docetaxel &amp; bortezomib for patients with advanced NSCLC. Determine the time to progression &amp; overall survival, assess toxicities, determine changes in serum proteomics patterns</measure>
    <time_frame>Expected average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel</description>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2A</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2B</arm_group_label>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_label>Phase I - Dose Level 4</arm_group_label>
    <arm_group_label>Phase I - Dose Level 5</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>VELCADE</other_name>
    <other_name>PS-341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel</description>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2A</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2B</arm_group_label>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_label>Phase I - Dose Level 4</arm_group_label>
    <arm_group_label>Phase I - Dose Level 5</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel</description>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2A</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2B</arm_group_label>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_label>Phase I - Dose Level 4</arm_group_label>
    <arm_group_label>Phase I - Dose Level 5</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or
             stage IV NSCLC

          -  Age &gt; 18 years

          -  ECOG PS &lt; 2

          -  No prior chemotherapy

          -  Measurable disease

          -  Signed informed consent

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate hepatic function

        Exclusion Criteria:

          -  Untreated clinically active brain metastasis

          -  Radiotherapy within 2 weeks prior to initiation of protocol therapy

          -  Treatment with any investigational therapy within 4 weeks prior to enrollment

          -  History of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma
             on situ of the cervix) within the last 5 years

          -  Patients in their reproductive age group should use an effective method of birth
             control. Men and women of childbearing potential must be willing to consent to using
             effective contraception while on treatment and for at least 3 months thereafter.
             Patients who are breast-feeding will be excluded from the study. Women of childbearing
             potential must have a negative pregnancy test.

          -  Major surgery within 3 weeks prior to enrollment

          -  Use of immunosuppressive agents including systemic corticosteroids within 4 weeks
             prior to enrollment (corticosteroids are permitted as physiological replacement
             therapy or as supportive care for nausea and emesis)

          -  Known history of Human immunodeficiency virus infection

          -  Any co-morbidity or condition of sufficient severity to limit full compliance with the
             protocol per assessment by the investigator

          -  Concurrent serious medical infection or illness, or psychiatric illness likely to
             interfere with participation in this clinical study.

          -  History of known hypersensitivity to docetaxel or other drugs formulated with
             polysorbate 80, bortezomib, boron or mannitol

          -  Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.

          -  Myocardial infarction within 6 months prior to enrollment or has New York Hospital
             Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conduction system abnormalities. Prior to study entry, any
             ECG abnormality at Screening has to be documented by the investigator as not medically
             relevant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandra P. Belani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Chandra P. Belani</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>advanced non small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

